Black Swan PharmaceuticalsDeveloping the next generation of RNA-targeted therapeutics
Black Swan Pharmaceuticals (BSP) is a biotechnology company dedicated to the discovery of innovative gene targeting therapeutics for Amyotrophic Lateral Sclerosis (ALS) and other devastating neurological disorders.
Our primary aim is to accelerate the pre-clinical development of potential breakthrough therapies and facilitate their rapid progression to the patients so desperately in need of them.
BSP is employing its genetic therapy expertise to identify drug targets for our platform of synthetic antisense RNA-based therapeutics. Our current focus is on developing treatments for the delay of progression or prevention of ALS.